Cytokinetics Inc. Stock
Price
Target price
€72.22
€72.22
-4.250%
-3.16
-4.250%
€81.26
13.07.26 / Tradegate
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cytokinetics Inc. Stock
Cytokinetics Inc. took a tumble today and lost -€3.160 (-4.250%).
The stock is an absolute favorite of our community with 41 Buy predictions and no Sell predictions.
As a result the target price of 81 € shows a slightly positive potential of 12.16% compared to the current price of 72.22 € for Cytokinetics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cytokinetics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -4.250% | -3.475% | 19.096% | 127.107% | 34.991% | 147.329% | 351.375% |
| Evolus Inc | -1.570% | -7.508% | -2.151% | -29.475% | 3.523% | -14.515% | -43.580% |
| Heron Therapeutics Inc. | -2.730% | -3.021% | 5.293% | -80.767% | -67.145% | -69.752% | -96.826% |
| Rhythm Pharmaceuticals | -1.060% | -2.604% | 23.026% | 25.503% | 0.000% | 567.857% | 477.160% |
Comments
Cytokinetics (CYTK) was upgraded by UBS Group AG from "neutral" to "buy".
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its price target raised by Mizuho from $100.00 to $118.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for CYTK provided by MarketBeat
News
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYKORZO’s launch is outperforming expectations, with Cytokinetics saying early prescriptions
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK), exercised 15,000 options for common stock and immediately sold the resulting
